MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Regeneron Pharmaceuticals Inc

Închisă

SectorSănătate

625.29 1.37

Rezumat

Modificarea prețului

24h

Curent

Minim

610.05

Maxim

627.04

Indicatori cheie

By Trading Economics

Venit

-423M

918M

Vânzări

69M

3.8B

P/E

Medie Sector

16.529

63.778

EPS

12.07

Randament dividend

0.56

Marjă de profit

24.219

Angajați

15,106

EBITDA

-534M

1.1B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+51.62% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.56%

2.39%

Următoarele câștiguri

29 apr. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-5B

70B

Deschiderea anterioară

623.92

Închiderea anterioară

625.29

Sentimentul știrilor

By Acuity

52%

48%

321 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Regeneron Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 feb. 2025, 12:13 UTC

Câștiguri

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

8 iul. 2024, 12:00 UTC

Câștiguri

Regeneron Expects Earnings Hit After $24 Million R&D Charge

28 feb. 2025, 12:00 UTC

Top știri

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 feb. 2025, 11:58 UTC

Câștiguri

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4 feb. 2025, 11:37 UTC

Câștiguri

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4 feb. 2025, 11:37 UTC

Câștiguri

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4 feb. 2025, 11:36 UTC

Câștiguri

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4 feb. 2025, 11:35 UTC

Câștiguri

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

4 feb. 2025, 11:35 UTC

Câștiguri

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

4 feb. 2025, 11:34 UTC

Câștiguri

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

4 feb. 2025, 11:34 UTC

Câștiguri

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

4 feb. 2025, 11:32 UTC

Câștiguri

Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase >REGN

4 feb. 2025, 11:31 UTC

Câștiguri

Regeneron Pharma Initiates Quarterly Cash Dividend Program >REGN

31 ian. 2025, 08:30 UTC

Achiziții, Fuziuni, Preluări

It's Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders. -- Barrons.com

28 ian. 2025, 10:30 UTC

Top știri

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

31 oct. 2024, 13:58 UTC

Câștiguri

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD

31 oct. 2024, 10:52 UTC

Câștiguri

Regeneron Earnings Top Views For Biotech Giant -- IBD

31 oct. 2024, 10:34 UTC

Câștiguri

Regeneron Pharma 3Q Adj EPS $12.46 >REGN

31 oct. 2024, 10:33 UTC

Câștiguri

Regeneron Pharma 3Q EPS Cut 43c by Acquired IPR&D Charge >REGN

31 oct. 2024, 10:33 UTC

Câștiguri

Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3% to $1.54B >REGN

31 oct. 2024, 10:32 UTC

Câștiguri

Regeneron Pharma: 3Q Dupixent Global Net Sales Recorded by Sanofi Rose 23% to $3.82B >REGN

31 oct. 2024, 10:30 UTC

Câștiguri

Regeneron Pharma 3Q Rev $3.72B >REGN

31 oct. 2024, 10:30 UTC

Câștiguri

Regeneron Pharma 3Q EPS $11.54 >REGN

31 oct. 2024, 10:30 UTC

Câștiguri

Regeneron Pharma 3Q Net $1.34B >REGN

25 oct. 2024, 20:25 UTC

Câștiguri

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

1 aug. 2024, 11:50 UTC

Câștiguri

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

1 aug. 2024, 10:37 UTC

Câștiguri

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

1 aug. 2024, 10:30 UTC

Câștiguri

Regeneron Pharma 2Q EPS $12.41 >REGN

1 aug. 2024, 10:30 UTC

Câștiguri

Regeneron Pharma 2Q Net $1.43B >REGN

1 aug. 2024, 10:30 UTC

Câștiguri

Regeneron Pharma 2Q Rev $3.55B >REGN

Comparație

Modificare preț

Regeneron Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

51.62% sus

Prognoză pe 12 luni

Medie 948.55 USD  51.62%

Maxim 1,182 USD

Minim 575 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRegeneron Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

20 ratings

16

Cumpărare

3

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

N/A / 662.33Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

321 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.